Siemens Healthineers: profit outlook raised, revenue trimmed, new deals build demand
Profit guidance raised, revenue growth cut Siemens Healthineers raised its fiscal 2026 earnings per share forecast to €2.35–2.45 but lowered comparable revenue growth to 3.5–4.0%. Profit is improving, but slower sales growth and tariff/pricing pressures keep a lid on the stock.
This is the single biggest company-specific event of the period and directly explains the mixed share price reaction.
New partnerships expand cancer and liver diagnostics Siemens Healthineers teamed up with Novo on non-invasive liver diagnostics and with Thailand's PRINC on advanced cancer care, including radiotherapy equipment. These deals open recurring revenue streams and embed its tools in more hospitals.
Fresh commercial wins show real demand for its products and support future revenue growth.
Surveys and reports point to strong lab and imaging demand A Siemens Healthineers survey found 54% of U.S. healthcare executives prioritize lab equipment upgrades, and a company report highlighted stroke care gaps in Southeast Asia. Both signal growing demand for its diagnostic and imaging solutions.
These demand indicators support the bull case for Siemens Healthineers' core segments.
AI imaging and MRI markets forecast to grow strongly Industry reports project the AI medical imaging market will reach $19.4 billion by 2035 and the MRI systems market $9.68 billion by 2031, with Siemens Healthineers named a key player. This supports long-term demand for its imaging and AI products.
Market growth forecasts reinforce the structural growth story behind the stock.